Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:NTRA

Natera Q3 2026 Earnings Date & Estimates

Natera logo
$397.77 -2.94 (-0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$398.18 +0.41 (+0.10%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Natera in Q3 2026

Natera is expected to post earnings of -$0.2567 per share on revenue of $707.39 million. In the same quarter a year earlier Natera reported -$0.64 per share on revenue of $592.18 million. Natera last reported on August 6, 2026, posting -$0.47 per share and beating the -$0.4939 consensus estimate. Natera has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.2567
Expected Revenue
$707.39 million
Prior-Year EPS
-$0.64
Prior-Year Revenue
$592.18 million
Expected Revenue Growth
+19.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.47 (Beat by +$0.0239)
Last Quarter Revenue
$752.75 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Natera Q3 2026 Earnings FAQ

Natera (NASDAQ:NTRA) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Natera's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Natera to post earnings of -$0.2567 per share for Q3 2026.

The consensus revenue estimate for Natera is $707.39 million for Q3 2026.

Natera Earnings Headlines

How FDA Breakthrough Status For Natera’s Multi‑Cancer Test (NTRA) Has Changed Its Investment Story
October 10 at 5:44 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-breakthrough-status-natera-multi-151256609.html
Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough News
October 10 at 5:44 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/natera-ntra-stock-may-33-141643092.html
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
October 12 at 1:00 AM  |  Weiss Ratings (Ad)
Natera, Inc. (NASDAQ:NTRA) Stock Has Average Target Price of $353.45
October 10 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104862
Natera receives FDA breakthrough device designation for multi-cancer early detection blood test
October 9 at 3:38 PM  |  msn.comhttps://www.msn.com/en-us/news/other/natera-receives-fda-breakthrough-device-designation-for-multi-cancer-early-detection-blood-test/ar-AA2dTHXc
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
October 9 at 9:03 AM  |  marketscreener.comM
See More Natera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Natera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Natera and other key companies, straight to your email.

About Natera

Natera (NASDAQ:NTRA) is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders. Natera also offers testing related to fertility and pregnancy management.

In oncology, the company’s Signatera test is designed to detect and monitor minimal residual disease and molecular recurrence using personalized, tumor-informed assays. Its transplant portfolio includes Prospera, which analyzes donor-derived cell-free DNA to help monitor for potential organ rejection. Natera was founded in 2004 and is headquartered in Austin, Texas. The company serves healthcare providers and patients in the United States and select international markets and is led by Chief Executive Officer Steve Chapman.

View Natera Profile
Earnings Tools